Fr520 IMMUNOMODULATOR CO-THERAPY IMPROVES MEDICATION PERSISTENCE OF FIRST-LINE ANTI-TUMOR NECROSIS FACTOR AGENTS AND FIRST-LINE VEDOLIZUMAB, BUT NOT SECOND-LINE THERAPY, IN MODERATE-TO-SEVERE ULCERATIVE COLITIS
Gastroenterology（2021）
关键词
co-therapy,first-line,anti-tumor,first-line,second-line,moderate-to-severe
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要